opdualag (nivolumab and relatlimab) injection

How It Works

Nivolumab is a PD-1 (programmed death-1) inhibitor, while relatlimab is a LAG-3 (lymphocyte-activation gene 3) inhibitor. Both drugs work by blocking the pathways that cancer cells use to evade the immune system. Nivolumab inhibits the PD-1 pathway, which allows T cells to recognize and attack cancer cells. Relatlimab inhibits the LAG-3 pathway, which further enhances the T cell response against tumors. Together, these drugs provide a synergistic effect, boosting the immune system’s ability to target and destroy cancer cells.

Side Effects

• Fatigue
• Diarrhea
• Rash
• Pruritus (itching)
• Nausea
• Decreased appetite
• Musculoskeletal pain
• Infusion-related reactions
• Elevated liver enzymes
• Hypothyroidism
• Pneumonitis
• Colitis

Indications

• Advanced or metastatic melanoma
• Other cancers as determined by ongoing clinical trials and approvals

Contraindications

• Severe hypersensitivity to nivolumab, relatlimab, or any of the excipients in the formulation
• Pregnancy and breastfeeding (due to potential harm to the fetus or infant)

Price Comparison in Different Countries

Top 5 Global Pharmaceutical Brands

1. Pfizer
2. Novartis
3. Roche
4. Sanofi
5. GlaxoSmithKline (GSK)

Conclusion

Opdualag (nivolumab and relatlimab) is a novel combination immunotherapy that leverages the power of the immune system to combat advanced cancers, particularly melanoma. By inhibiting both the PD-1 and LAG-3 pathways, this drug enhances T cell activity against cancer cells. Patients should be aware of potential side effects and contraindications, and should work closely with their healthcare providers to determine the best course of treatment. The cost of Opdualag can vary significantly between countries, reflecting differences in healthcare systems and pricing structures. Exploring financial assistance options may help manage the cost of treatment.